DCPH

Deciphera Pharmaceuticals, Inc. (DCPH) | Rumor.io

Deciphera Pharmaceuticals

DCPH

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about DCPH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Jun 11

Deciphera Pharmaceuticals (DCPH) has been acquired by Ono Pharmaceutical.
Ono Pharmaceutical has completed its tender offer for Deciphera Pharmaceuticals.
Shareholders of Deciphera Pharmaceuticals can no longer trade their shares after the acquisition.

Generated by AI

Sentiment

Of the messages about DCPH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	30.77% -45.42
Bearish	—	—	—	69.23% +45.42

Bullish· Apr 29

Deciphera Pharmaceuticals, Inc. ($DCPH) has been acquired by ONO Pharmaceutical for $2.4 billion, with shareholders to receive $25.60 per share in cash.
The acquisition is expected to close in Q3 2024, subject to regulatory and shareholder approvals, and will expand ONO's oncology portfolio with Deciphera's kinase inhibitor expertise.
The deal will help Deciphera expand its cancer treatment pipeline and boost coverage in the U.S. and Europe, and is seen as a strategic move to accelerate the delivery of innovative cancer therapies worldwide.

Bearish· Nov 23

The company lacks a strong pipeline, which could hinder its growth prospects.
Deciphera Pharmaceuticals has a history of closing red, indicating a potential downtrend.
The stock's valuation is considered ridiculous, with some investors perceiving it as overpriced.

Generated by AI

Topics

Of the messages about DCPH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	6.12%
Announcements	100%	100%	100%	93.88%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	0%

Earnings· Mar 28

Deciphera Pharmaceuticals reported 4Q and YE 2017 financial results.
The company highlighted recent corporate activity.
DCPH's earnings announcement included key financial data.

Analysts· Nov 8

Analysts' price targets for DCPH range from $10 to $78, with an average of $61.80, representing a 600.68% change from the last price.
Deciphera Pharmaceuticals has a 90% buy consensus among analysts, with 8 analysts covering the stock.
Analysts have downgraded DCPH due to the failure of the company's Qinlock in 2L gastrointestinal stromal tumor (GIST), with some price targets being cut by as much as $50.

Announcements· Apr 29

Deciphera Pharmaceuticals, Inc. (DCPH) has agreed to be acquired by ONO Pharmaceutical for $2.4 billion, with shareholders to receive $25.60 per share in cash.
The acquisition expands ONO's oncology portfolio with Deciphera's kinase inhibitor expertise and is expected to accelerate the delivery of innovative cancer therapies worldwide.
The deal includes a tender offer followed by a merger, expected to close in Q3 2024, with Deciphera to continue operations as a standalone entity within the ONO Group from Waltham, MA.

Generated by AI

Community

Of the messages about DCPH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	86%
Newcomers	0%	0%	0%	14%

Regulars· Apr 29

The acquisition of Deciphera Pharmaceuticals, Inc. by ONO Pharmaceutical for $2.4 billion is confirmed, with shareholders set to receive $25.60 per share in cash.
Deciphera's expertise in kinase drug discovery is a key factor in the acquisition, with the company's QINLOCK treatment approved for gastrointestinal stromal tumor and vimseltinib in Phase 3 trials.
The transaction is expected to close in Q3 2024, with Deciphera's shares halted on April 29, 2024, due to the news.

Newcomers· May 3

Deciphera Pharmaceuticals is being acquired by Ophthotech for $2.4B, expanding Ophthotech's presence in the US and Europe.
The acquisition will help Ophthotech broaden its global coverage and enhance its pipeline.
The deal is seen as a positive development for Ophthotech, but its size is relatively small compared to other deals in the biotech sector.

Generated by AI

Also Discussed

Investors talking about DCPH also mention

#	Name	Attention
1	ALLK - Allakos Inc.	——
2	BPMC - Blueprint Medicines Corporation	——
3	RETA - Reata Pharmaceuticals, Inc.	——
4	Olema Pharmaceuticals, Inc.OLMA	0%new
5	Quince Therapeutics Inc.QNCX	0%+0
6	Rafael Holdings Inc.RFL	0%0
7	Pulmonx CorporationLUNG	0%0
8	Protagonist Therapeutics, Inc.PTGX	0%new
9	Tokyo Lifestyle Co., Ltd. American Depositary SharesTKLF	0%0
10	GRTX - Galera Therapeutics, Inc.	——